Literature DB >> 29098230

RNA-mediated TILDA for improved cell capacity and enhanced detection of multiply-spliced HIV RNA.

Hannah M Pezzi1, Scott M Berry, David J Beebe, Rob Striker.   

Abstract

Quantification of the HIV viral reservoir is critical to understanding HIV latency, advancing patient care and ultimately achieving a cure. To quantify the reservoir, a new metric was recently introduced, which quantified cells carrying multiply spliced HIV RNA. The developed assay, Tat/rev Induced Limiting Dilution Assay (TILDA), enables quantification of cells containing multiply-spliced HIV RNA events as an indicator of reservoir size. Due to TILDA's reliance on a limiting dilution format paired with the rarity of target events, numerous individual reactions are required to obtain a single endpoint. The current assay embodiment uses a whole cell input to detect target RNA sequences without the traditional preceding nucleic acid purification steps. Thus, while the direct measurement of target events from whole cells significantly streamlines the workflow, there is a cost in sensitivity and assay throughput. Here, we apply a new technique for rapid RNA isolation, Exclusion-Based Sample Preparation, to TILDA, with the goal of alleviating these limitations without significantly adding to the workflow. By combining TILDA with multiplexed RNA extraction enabled by exclusion-based sample preparation, assay sensitivity and capacity are improved while maintaining assay simplicity, advancements that could facilitate eventual clinical implementation in detecting rare events in patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29098230      PMCID: PMC5733636          DOI: 10.1039/c7ib00112f

Source DB:  PubMed          Journal:  Integr Biol (Camb)        ISSN: 1757-9694            Impact factor:   2.192


  27 in total

Review 1.  Pre-PCR processing: strategies to generate PCR-compatible samples.

Authors:  Peter Rådström; Rickard Knutsson; Petra Wolffs; Maria Lövenklev; Charlotta Löfström
Journal:  Mol Biotechnol       Date:  2004-02       Impact factor: 2.695

2.  Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells.

Authors:  M Vesanen; M Markowitz; Y Cao; D D Ho; K Saksela
Journal:  Virology       Date:  1997-09-15       Impact factor: 3.616

3.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Single cell transcript analysis of human immunodeficiency virus gene expression in the transition from latent to productive infection.

Authors:  H Peng; T A Reinhart; E F Retzel; K A Staskus; M Zupancic; A T Haase
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

5.  Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA.

Authors:  Alexander O Pasternak; Karen W Adema; Margreet Bakker; Suzanne Jurriaans; Ben Berkhout; Marion Cornelissen; Vladimir V Lukashov
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

6.  A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.

Authors:  Francesco Andrea Procopio; Rémi Fromentin; Deanna A Kulpa; Jessica H Brehm; Anne-Gaelle Bebin; Matthew C Strain; Douglas D Richman; Una O'Doherty; Sarah Palmer; Frederick M Hecht; Rebecca Hoh; Richard J O Barnard; Michael D Miller; Daria J Hazuda; Steven G Deeks; Rafick-Pierre Sékaly; Nicolas Chomont
Journal:  EBioMedicine       Date:  2015-06-27       Impact factor: 8.143

7.  Efficient sample preparation from complex biological samples using a sliding lid for immobilized droplet extractions.

Authors:  Benjamin P Casavant; David J Guckenberger; David J Beebe; Scott M Berry
Journal:  Anal Chem       Date:  2014-06-13       Impact factor: 6.986

8.  Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.

Authors:  Ya-Chi Ho; Liang Shan; Nina N Hosmane; Jeffrey Wang; Sarah B Laskey; Daniel I S Rosenbloom; Jun Lai; Joel N Blankson; Janet D Siliciano; Robert F Siliciano
Journal:  Cell       Date:  2013-10-24       Impact factor: 41.582

9.  Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay.

Authors:  Gregory M Laird; Evelyn E Eisele; S Alireza Rabi; Jun Lai; Stanley Chioma; Joel N Blankson; Janet D Siliciano; Robert F Siliciano
Journal:  PLoS Pathog       Date:  2013-05-30       Impact factor: 6.823

10.  Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.

Authors:  Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow
Journal:  PLoS One       Date:  2009-05-18       Impact factor: 3.240

View more
  3 in total

1.  An Optimized Tat/Rev Induced Limiting Dilution Assay for the Characterization of HIV-1 Latent Reservoirs.

Authors:  Swarnima Mishra; Yuvrajsinh Gohil; Kavita Mehta; Anish D'silva; Afzal Amanullah; Deepak Selvam; Neelam Pargain; Narendra Nala; G N Sanjeeva; Udaykumar Ranga
Journal:  Bio Protoc       Date:  2022-04-20

2.  Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA.

Authors:  Cynthia Lungu; Francesco A Procopio; Ronald J Overmars; Rob J J Beerkens; Jolanda J C Voermans; Shringar Rao; Henrieke A B Prins; Casper Rokx; Giuseppe Pantaleo; David A M C van de Vijver; Tokameh Mahmoudi; Charles A B Boucher; Rob A Gruters; Jeroen J A van Kampen
Journal:  Viruses       Date:  2020-09-02       Impact factor: 5.048

3.  An Improved Tat/Rev Induced Limiting Dilution Assay With Enhanced Sensitivity and Breadth of Detection.

Authors:  Kavita Mehta; Yuvrajsinh Gohil; Swarnima Mishra; Anish D'silva; Afzal Amanullah; Deepak Selvam; Neelam Pargain; Narendra Nala; G N Sanjeeva; Udaykumar Ranga
Journal:  Front Immunol       Date:  2021-08-05       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.